›› 2017, Vol. 37 ›› Issue (9): 1276-.doi: 10.3969/j.issn.1674-8115.2017.09.015

Previous Articles     Next Articles

Role of DNA methyltransferase 3A in hematological malignancies#br#

SHI Xiao-dong, DAI Yu-jun, WANG Yue-ying   

  1. Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
  • Online:2017-09-28 Published:2017-10-10
  • Supported by:
     National Natural Science Foundation of China, 81570151; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support, 20152507; Shanghai Jiao Tong University SMC-Morningstar Young Scholars Program, 2014

Abstract: DNA methyltransferase 3A (DNMT3A) is one of the critical epigenetic modifiers responsible for de novo DNA methylation. DNMT3A mutations are identified in some kinds of hematological malignancies, especially in acute myeloid leukemia (AML) with high frequency, indicating poor prognosis. Recent researches have shown that abnormalities of epigenetic related genes such as DNMT3A play important roles in the development and progression of hematological malignancies, which was named as class Ⅲ mutation associated with the pathogenesis of AML. In this review, the progresses of clinical and basic researches about DNMT3A mutation in hematological malignancies were summarized.

Key words: DNA methyltransferase 3A, epigenetic modification, gene mutation, hematological malignancy